# Vaccine and Treatment Evaluation Units (VTEU)

> **NIH NIH UM1** · BAYLOR COLLEGE OF MEDICINE · 2021 · $2,614,800

## Abstract

ABSTRACT
This supplement request is for a Phase 3, randomized, observer-blind, placebo-controlled study
to evaluate the efficacy, safety and immunogenicity, of a SARS-CoV-2 recombinant spoke
protein nanoparticle vaccine (SARS-CoV-2 rS) with Matric-M1TM adjuvant in adult participants
over 18 years of age who have no known history of SARS-CoV-2 infection but whose locations
or circumstances put them at appreciable risk of acquiring COVID-19 and/or SARS-CoV-2
infection. This request also relates to other COVID 19 activities.

## Key facts

- **NIH application ID:** 10296949
- **Project number:** 3UM1AI148575-02S4
- **Recipient organization:** BAYLOR COLLEGE OF MEDICINE
- **Principal Investigator:** HANA M EL SAHLY
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $2,614,800
- **Award type:** 3
- **Project period:** 2020-12-23 → 2022-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10296949

## Citation

> US National Institutes of Health, RePORTER application 10296949, Vaccine and Treatment Evaluation Units (VTEU) (3UM1AI148575-02S4). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10296949. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*